Sign in

    Tim

    Director in the Equity Capital Markets group at Piper Sandler

    Tim Reichert is a Director in the Equity Capital Markets group at Piper Sandler, specializing in the origination and execution of equity offerings for growth sector issuers. Since joining Piper Sandler in 2013, he has contributed to numerous successful equity capital raises, supporting the firm’s reputation for connecting high-growth companies with institutional capital. Based in New York, Reichert has focused his career in capital markets and holds a bachelor's degree in economics from Trinity College. His professional credentials highlight his expertise in advising issuers within the financing and equity capital markets arena.

    Tim's questions to MOND leadership

    Tim's questions to MOND leadership • Q2 2024

    Question

    Asked about the competitive dynamics in marketing and any planned strategy changes for the second half of the year. Also inquired about the outlook for airfares into late 2024 and 2025, considering airline capacity reductions.

    Answer

    The company believes its current market share-gaining strategy is working well, differentiated by its AI platform, and feels well-positioned now that capital constraints are being resolved. Regarding airfares, despite airline capacity discipline, pricing is still being used as a competitive tool. Air prices are expected to remain soft through the end of the year before stabilizing and recovering in early 2025. Mondee's global platform allows it to pivot to stronger markets to offset softness.

    Ask Fintool Equity Research AI

    Tim's questions to CARA leadership

    Tim's questions to CARA leadership • Q3 2023

    Question

    Asked for an update on the expected KORSUVA inventory burn-down and whether monetizing the oral difelikefalin program is being considered to extend the cash runway.

    Answer

    Due to the CMS rule, Fresenius is reallocating inventory, which will lead to a disconnection between demand and sales for the next two quarters and downward pressure on future sales. The company confirmed it is looking for an ex-U.S. partner for oral difelikefalin, which is part of its plan but not included in the current cash runway guidance.

    Ask Fintool Equity Research AI